# Kaleido Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kaleido-biosciences

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.kaleido.com
- Total disclosed funding: $161M
- Latest round: Series C (Jun 25, 2018)
- Investors on record: 5

## About

Kaleido Biosciences, Inc. is focused on developing innovative solutions in the life sciences and healthcare sectors, particularly through advanced platforms that enhance clinical trials, patient engagement, and data management.Kaleido Biosciences, Inc. was founded in 2015 and is headquartered in Lexington, US. The company is engaged in providing innovative platforms for clinical trials and patient engagement. In February 2019, Kaleido raised USD 75 mn in an IPO, selling shares on NASDAQ. The most recent funding round was a Private Placement, where USD 60.40 mn was raised in February 2021, following which the total amount raised by the company is USD 60.40 mn. The current CEO is Daniel Menichella.Kaleido provides advanced platforms designed to streamline clinical trials and enhance patient engagement. Their solutions facilitate data management and address end-use cases such as drug development acceleration and effective patient recruitment. The company serves pharmaceutical and biotechnology firms, primarily in North America and Europe, ensuring compliance and operational efficiency.In the most recent year, 2021, Kaleido reported a revenue of USD 1.10 mn with an EBITDA of USD -84.60 mn.Kaleido's strategy for future growth includes the development of new product offerings aimed at enhancing clinical trial management and patient engagement. They are targeting expansion into additional markets in North America and Europe, with plans to leverage the recent funding of USD 60.40 mn to support these initiatives. However, in April 2022, Kaleido announced the discontinuation of operations, which may affect these growth plans.

## Funding rounds

- Series C, Jun 25, 2018, $101M — Flagship Pioneering, Invus [DUP], Fidelity Investments, Abu Dhabi Investment Council, Rock Springs Capital
- Series B, Sep 18, 2017, $60M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B, Series C
- Invus [DUP] — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Abu Dhabi Investment Council (https://capitalatlas.ai/funds/abu-dhabi-investment-council) — Series C
- Rock Springs Capital — Series C